| abstract |
The present invention relates to the use of compounds of formula II wherein R is hydrogen, tritium, hydroxy, amino, lower alkyl, cycloalkyl, lower alkoxy, halogen, cyano, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, phenyl, O-phenyl, -S-phenyl, optionally substituted with halogen or is benzyl, benzyloxy, NHC (O)-lower alkyl or pyridin-2,3 or 4-yl; R 1 is hydrogen, hydroxy or lower alkyl; R 2 is hydrogen or lower alkyl; aryl is an aromatic group selected from phenyl, naphthalen-1-yl or naphthalen-2-yl; hetaryl is an aromatic group containing at least one O, N or S ring atom, selected from the group consisting of pyridin-3-yl, pyrazolyl, benzofuran-3-yl, benzofuran-4-yl, benzofuran-5-yl, benzofuran-6 -yl, benzofuran-7-yl, thiophen-2-yl, thiophen-3-yl, benzo [b] thiophen-3-yl or indol-3-yl; n is 1, 2, 3, 4 or 5; when n is 2, 3, 4 or 5, R may be the same or not; the dotted line may or may not be a binding; and to their pharmaceutically active salts for the manufacture of drugs for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological disorders such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, sleep disorders and circadian rhythm and cardiovascular disorders. |